Vanilla

Vanilla (Vanilla planifolia Andrews): A Comprehensive Reference Article

1. Identity: Botanical and Chemical Classification

1.1 Botanical Identity

The orchid genus Vanilla (family Orchidaceae) consists of 110 species, three of which are cultivated for their commercial value related to aromas: Vanilla planifolia Jacks. ex Andrews, Vanilla tahitensis J.W. Moore, and Vanilla pompona Schiede. Vanilla planifolia is a species of vanilla orchid native to Mexico, Central America, Colombia, and Brazil, and it is one of the primary sources for vanilla flavouring due to its high vanillin content. Common names include flat-leaved vanilla and West Indian vanilla. Natural sources of the vanilla flavor are the pods of these tropical orchid plants; V. planifolia is the most widely traded species, followed by V. tahitensis.

Vanilla planifolia, the main source of the fragrant spice and flavoring, is a vine in the orchid family. Native to the Neotropics, in the wild vanilla grows from Mexico to Brazil in warm and humid climates, and is cultivated on tropical islands in the Indian Ocean such as Madagascar and Réunion. Today, Madagascar is the largest producer of natural vanilla with 75% of world production, followed by Indonesia, China, Mexico, and Papua New Guinea.

1.2 The Vanilla Bean and the Curing Process

The fruit of a fully mature vanilla orchid is called a vanilla "pod" or "bean." These beans are green, long, smooth, and slender, possess no flavour, and are almost odourless. To develop the characteristic vanilla flavour and aroma, green beans are subjected to a curing process commonly lasting three to six months. Traditional so-called "curing" processes involve scalding, sweating, and a long conditioning step that lasts several weeks or months and employs naturally occurring enzymatic reactions. Prior to sweating and conditioning, the beans are usually subjected to a short step of scalding in hot water at about 65°C.

The enzyme β-glucosidase is crucial in the release of vanillin during the curing process, which is essential for producing high-quality vanilla flavor. The enzymatic reactions in the vanilla beans converting its precursor glucovanillin to vanillin are believed to be mainly caused by residual plant enzymes, in particular glucosidase enzymes. The glucovanillin content in perfectly matured vanilla beans is about 10% per weight of dried vanilla beans on average, which can theoretically be converted into a maximum of 4.84% vanillin assuming complete conversion and no losses.

1.3 Common Commercial Forms and Preparations

Cured vanilla beans can be used as they are, but the vast majority are used for the extraction and the preparation of vanilla products, of which there are four basic types: vanilla extract (by far the most used vanilla product), vanilla oleoresin, vanilla absolute, and vanilla powder/sugar.

• Vanilla Extract: Vanilla extract is the most commonly used natural vanilla product in the food industry. It is a hydro-alcoholic solution containing the extracted aroma and flavor of vanilla beans, with 35–50% alcohol content. The FDA stipulates that the flavoring consists of 35% alcohol and contains 13.35 ounces of vanilla beans per gallon of alcohol.
• Vanilla Oleoresin: Vanilla oleoresin is prepared by solvent extraction of finely cut vanilla. It is solvent-extracted from cured beans, with the solvent subsequently removed, producing a thick, dark paste with intense vanilla flavour. Its excellent heat stability makes it ideal for baked goods and processed foods.
• Vanilla Powder: Vanilla powder consists of ground vanilla beans (including seeds and pod) or spray-dried extract on a maltodextrin carrier. It is used in dry mixes, protein powders, and applications where liquid vanilla would cause formulation issues.
• Vanilla Absolute: Vanilla absolute and vanilla tincture are used in the perfumery and pharmaceutical industries.
• Synthetic Vanillin: Less than 1% of the global vanillin production originates from the vanilla orchids; the vast majority is produced chemically from fossil fuels or by acid hydrolysis of lignin.

2. Traditional and Historical Use

2.1 Indigenous Mesoamerican Origins

Vanilla begins its story in the lush rainforests of Mesoamerica, where the Totonac people of modern-day Mexico cultivated the vanilla orchid (Vanilla planifolia) over 2,000 years ago. It is in Mexico where Vanilla planifolia is said to originate, entwined in the rich histories of both the Totonacs and the Aztecs. The Totonacs of Vera Cruz have a long history of vanilla cultivation that continues to remain a great source of pride for their people.

The Totonacs revered vanilla as a sacred gift from the gods, using it in rituals, perfumes, and as a flavoring for their chocolate-based drinks. The Totonacs have a deep and spiritual relationship with the land, and particularly with vanilla, which they consider a gift from the gods and which features heavily in several of the mythologies of the Totonac people.

2.2 Aztec Use

The Aztecs later adopted vanilla, calling it tlilxochitl (black flower) and blending it with cacao to create a luxurious beverage reserved for nobility. The Aztecs used vanilla in their recipe for xocolatl, an energizing chocolate beverage said to combat fatigue, in which they also mixed ground cacao seeds, ground corn, and chilli peppers. For the Aztecs, vanilla was so valuable that it was often used as a tribute to the emperor.

The naturalist and court physician to the king of Spain, Francisco Hernández de Toledo, mentions vanilla in reference to its role as one of three top contenders for Aztec aphrodisiacs. Following the arrival of the Spanish to Mexico, all the ancient flavourings for chocolate were eventually changed in order to make it more appealing to the European palate, with vanilla being the only consistent native flavouring to remain.

2.3 Introduction to Europe and Global Spread

In the early 16th century, Spanish explorer Hernán Cortés brought vanilla and cacao back to Europe after his conquest of the Aztec Empire. Initially, vanilla was used exclusively to flavor chocolate, just as it had been in Mesoamerica. It was not long, however, before European palates discovered its potential as a standalone flavor.

It was in 1519 that vanilla was exposed to the world with the Spanish invasion of the Aztecs. It was transported to Europe and the subsequent development of hand pollination techniques led to its expansion to other parts of the world. Vanilla planifolia played a large role in the early rural economy throughout Mexico, and by the 20th century had become a widely cultivated crop across the world.

3. Key Constituents and Active Compounds

3.1 Primary Constituent: Vanillin

Vanillin (3-methoxy-4-hydroxybenzaldehyde) is the main flavour component of vanilla extract from cured vanilla pods. Vanillin influences the vanilla flavor, contributing 1–2% weight/weight of the cured pods. Vanillin makes up 80% of the total aromatic compounds found in the pods of V. planifolia, in contrast to the 50% content of Vanilla × tahitensis pods.

Vanillin has different functional groups: an aldehyde, a hydroxyl, and an ether group, all attached to an aromatic ring. Vanillin (MW 152.15 g/mol) is a white or slightly yellow, dry powder that takes the form of liquid or pellets with large crystals, with a melting point of 178–181°F. It is very soluble in ethanol, diethyl ether, and acetone.

In the pod, vanillin is produced and stored as non-toxic vanillin glucoside. It is the key constituent of the natural vanilla flavour obtained from cured vanilla pods. A single hydratase/lyase type enzyme designated vanillin synthase (VpVAN) catalyses the direct conversion of ferulic acid and its glucoside into vanillin and its glucoside, respectively.

3.2 Additional Phytochemicals

Although the characteristic vanilla aroma is mainly due to vanillin, vanilla pods contain more than 60 aroma-active and more than 200 volatile compounds. Some of the other chemicals found in lesser amounts in the pods of Vanilla planifolia, such as guaiacol, 4-methylguaiacol, acetovanilone, and vanillic alcohol, also contribute to the perception of a vanilla flavor.

By gas chromatography-olfactometry (GC-O), acetovanillone exerts an aroma intensity as strong as vanillin even at 1000 times less concentration in V. planifolia. Vanillic acid is a naturally occurring phenolic acid and a major oxidative metabolite of vanillin, widely distributed in the plant kingdom and found in foods such as vanilla beans, green tea, wine, and fermented products. It is produced biosynthetically from ferulic acid or vanillin and serves as an intermediate substance in the microbial breakdown of lignin.

Several additional minor compounds in the pods contribute to and are responsible for the differences between the vanilla flavor and chemically derived vanillin. The aroma of vanilla beans is described as floral, plum/raisin, spicy, woody, and tobacco-like.

4. Mechanisms of Action

4.1 Antioxidant Activity

Vanillin has been reported to exhibit multifunctional effects, including antimutagenic, antiangiogenetic, anti-colitis, anti-sickling, and antianalgesic effects. However, results of studies on the antioxidant activity of vanillin are not fully consistent. Using multiple assay systems, vanillin showed stronger activity than ascorbic acid and Trolox in the ABTS⁺-scavenging assay but showed no activity in the DPPH radical- and galvinoxyl radical-scavenging assays. Vanillin showed much stronger antioxidant activity than ascorbic acid and Trolox in the ORAC assay and the oxidative hemolysis inhibition assay (OxHLIA).

In the ABTS⁺-scavenging assay, ORAC assay, and OxHLIA, vanillin reacted with radicals via a self-dimerization mechanism. This dimerization contributed to a high reaction stoichiometry against ABTS⁺ and AAPH-derived radicals.

4.2 Anti-Inflammatory Mechanisms

In lipopolysaccharide (LPS)-stimulated BV-2 microglial cells, vanillin significantly decreased the production of nitric oxide and pro-inflammatory cytokines, including IL-1β, TNF-α, and IL-6. Vanillin also reduced protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), as well as mRNA expression levels of IL-1β, TNF-α, and IL-6. Moreover, vanillin inhibited the phosphorylation of mitogen-activated protein kinases (MAPKs) and nuclear factor (NF)-κB.

4.3 Anti-Sickling Mechanism

Vanillin, as a food additive, covalently binds with sickle haemoglobin (HbS), inhibits cell sickling, and shifts the oxygen equilibrium curve towards the left. X-ray crystallographic studies with deoxyhemoglobin (HbA)-vanillin demonstrate that vanillin binds near His 103α, Cys 104α, and Gln 131β in the central water cavity. A secondary binding site is located between His 116β and His 117β. His 116β has been implicated as a polymer contact residue. Oxygen equilibrium, ektacytometry, and x-ray studies indicate that vanillin may act to decrease HbS polymerization via a dual mechanism: allosteric modulation to a high-affinity HbS molecule and by stereospecific inhibition of T-state HbS polymerization.

4.4 Blood-Brain Barrier Permeability

Even at high concentrations, vanillin demonstrates nontoxicity along with rapid absorption and the ability to cross the blood–brain barrier, making it a promising candidate for treating neurological diseases.

5. Scientific Evidence by Area of Use

5.1 Antioxidant and Hepatoprotective Effects

Evidence type: Animal (in vivo) and in vitro studies; no human clinical trials.

The antioxidant and anti-inflammatory effects of vanillin are considered important factors in the protection against liver injury and fibrosis. One study investigated the protective effects of vanillin against carbon tetrachloride (CCl₄)-induced hepatotoxicity in rats. Pretreatment with vanillin prior to CCl₄ administration significantly prevented the decrease in protein synthesis and the increase in plasma alanine (ALT) and aspartate (AST) aminotransferases. Furthermore, it inhibited hepatic lipid peroxidation and protein carbonyl formation, and attenuated the CCl₄-mediated depletion of antioxidant enzymes catalase and superoxide dismutase (SOD), as well as glutathione (GSH) levels in the liver. In addition, vanillin markedly attenuated the expression levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6, and prevented CCl₄-induced hepatic cell alteration and necrosis.

These findings are exclusively in animal and cell models. No human clinical trials have examined the hepatoprotective effects of vanilla or vanillin.

5.2 Anti-Inflammatory Effects

Evidence type: In vitro and animal studies; no human clinical trials.

The potent anti-inflammatory activities of vanillin and its derivatives have been thoroughly reviewed, with emphasis on anti-cancer, anti-infective, wound-healing, and neuroprotective health-promoting properties. Inflammation and thrombosis are implicated in several non-communicable chronic disorders, including cardiovascular diseases, diabetes, renal and neurodegenerative disorders, skin diseases, and cancer. Natural phytochemicals like phenolic compounds have been proposed to reduce the inflammatory burden with several health benefits against these disorders.

The primary mechanistic evidence originates from cell culture and rodent models. The mechanisms of action, along with outcomes from in vitro and in vivo studies and clinical trials, on the benefits of these vanillin-based phenolic bioactives against each of these disorders are discussed in published reviews, although robust human clinical trial data for vanilla extract per se remains limited.

5.3 Antimicrobial Activity

Evidence type: In vitro and animal (mouse colitis model) studies.

Since centuries the vanilla bean Vanilla planifolia has been well-known for its healing properties in traditional medicine. Furthermore, its main constituents are used as preservatives and aromatics in the food industry. The plant contains more than 200 molecular components, of which the phenolic aldehyde vanillin accounts for the main part of its medicinal activity, constituting one to two percent weight by weight (w/w) in cured vanilla pods.

Given the increasing prevalence of infections caused by MDR bacteria such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species (ESKAPE pathogen complex), it is pivotal to explore novel alternative or adjunct treatment options such as phytochemicals with antibiotic properties. Vanillin seems to work synergistically with certain antibiotics against common bacteria, which may prove extremely useful as bacteria become increasingly antibiotic-resistant. Among several plant extracts, vanillin could serve as a potential anti-virulence therapy, mainly by controlling quorum sensing (QS) as an inhibitor of the pqs QS system, probably via the PqsR receptor.

These findings are predominantly in vitro. Clinical application in human infectious disease has not been established.

5.4 Neuroprotective and Neurodegenerative Disease Effects

Evidence type: In vitro and animal studies; no confirmed human clinical trials for vanilla or vanillin as a standalone neuroprotective agent.

Vanillin is a natural phenolic compound found in several vanilla beans and widely used for food, cosmetic, and pharmaceutical products. Besides its industrial applications, vanillin possesses several beneficial effects for human health, such as antioxidant activity, in addition to anti-inflammatory, anti-mutagenic, anti-metastatic, and anti-depressant properties. Moreover, vanillin exhibits neuroprotective effects on multiple neurological disorders and neuropathophysiological conditions.

Vanillin exhibits neuroprotective effects on multiple neurological disorders and neuropathophysiological conditions. A 2023 review examined the mechanisms of action by which vanillin prevents neuroinflammation and neurodegeneration in vitro and in vivo systems, providing updated views on the beneficial properties of this molecule in chronic neurodegenerative diseases.

The studies presented in this review reveal several beneficial properties of vanillin in neuroprotection. Although different molecular mechanisms are involved in the prevention of neuroinflammation and neurodegeneration by vanillin, positive effects have been observed in several neurodegenerative disorders and neuropathophysiological conditions, both in vitro and in vivo. Evidence remains preclinical. No randomized controlled trials in humans have specifically evaluated vanillin for any neurodegenerative condition.

5.5 Anti-Sickling Activity (Sickle Cell Disease)

Evidence type: In vitro, animal studies, and limited early-phase clinical investigation of vanillin derivatives.

It had been known for 30 years that vanillin, the compound that gives the vanilla bean its flavor, protects red blood cells with sickle cell disease from assuming the sickle shape that obstructs blood vessels. However, this effect previously occurred only in test tubes, because vanillin normally breaks down in the digestive tract before reaching the bloodstream.

Vanillin has no therapeutic effect if given orally because orally administered vanillin is rapidly decomposed in the upper digestive tract. To overcome this problem, a vanillin prodrug, MX-1520, which is biotransformed to vanillin in vivo, was synthesized. Studies using transgenic sickle mice showed that oral administration of MX-1520 prior to hypoxia exposure significantly reduced the percentage of sickled cells in the blood. The survival time under severe hypoxic conditions was prolonged from 6.6 ± 0.8 min in untreated animals to 28.8 ± 12 min (P < 0.05) and 31 ± 7.5 min (P < 0.05) for doses of 137.5 and 275 mg/kg, respectively.

Scientists spearheaded the development of a novel class of oral anti-sickling drugs based on natural aromatic aldehydes, like vanillin from vanilla extract. This groundbreaking work demonstrated the potential of aromatic aldehydes as allosteric effectors to stabilize the high O₂-affinity state of hemoglobin S (HbS) and reduce its tendency to polymerize, thereby inhibiting RBC sickling. This scientific foundation eventually led to FDA approval of the first aromatic aldehyde drug, Voxelotor.

Vanillin itself undergoes extensive metabolism, resulting in low bioavailability, low potency, and an overall reduction in its pharmacologic effect when administered orally. The approved drug Voxelotor is a structurally distinct aromatic aldehyde derivative, not vanillin itself.

5.6 Anticancer and Antimutagenic Effects

Evidence type: In vitro and limited animal studies; mixed findings; no human clinical trials.

An in vitro study demonstrated vanillin's cytostatic and cytolytic properties on human colorectal cancer cell line HT-29. Previous studies reported that vanillin is a good antimutagen and anticarcinogen. However, there are also contradicting findings showing that vanillin was a comutagen and cocarcinogen.

Vanillin (1000 µg/mL) inhibited the proliferation of HT-29 colon cancer cells, where significant cell arrest occurred during the G0/G1 phase and an increase in apoptotic cells in sub-G0 phase was observed.

In animal models of breast cancer, in a study examining the effect of vanillin on the growth and metastasis of 4T1 mammary adenocarcinoma cells in BALB/c mice, orally administered vanillin showed significantly reduced numbers of lung-metastasized colonies compared to controls. In vitro studies revealed that vanillin, at concentrations that were not cytotoxic, inhibited invasion and migration of cancer cells and inhibited the enzymatic activity of MMP-9 secreted by the cancer cells.

In vivo, the combination of vanillin with 5-fluorouracil (5-Fu) yielded a notable synergy in inhibiting tumor growth and inducing apoptosis in colorectal cancer models. Vanillin exhibits anti-invasive and anti-metastatic activities by suppressing the expression of MMP-9, via signaling pathways such as PI3K, nuclear factor (NF)-κB, and STAT3/HIF-1α.

Critically, results showed that vanillin consumed orally had no effect on aberrant crypt foci (ACF) in a colon carcinogenesis model. However, high concentrations (300 mg/kg body weight) of vanillin administered through intraperitoneal injection could increase ACF density and multiplicity. This highlights dose-dependency and route-of-administration concerns. No human oncology clinical trials for vanillin exist.

5.7 Endometriosis

Evidence type: In vitro and mouse model; no human data.

As the main component of vanilla bean extract, vanillin is widely used as a flavoring agent in the food, pharmaceutical, and cosmetic industries. It is known for its anti-inflammatory, antibacterial, and antitumor properties. Results from a mouse endometriosis model showed that vanillin significantly inhibited the growth of endometrial lesions; compared with the control group, the weight and volume of lesions were reduced considerably in the vanillin-treated group, showing its ability to inhibit cell proliferation. Most importantly, the data showed that the vanillin treatment had only minimal effects on the eutopic endometrium with respect to the pregnancy process, indicating its safety for use in treating endometriosis in adults in the experimental context. This remains preclinical evidence only.

5.8 Traditional Indications Without Strong Scientific Evidence

Some of these extracts contain a chemical called coumarin, which is banned by the FDA. People use vanilla for conditions such as intestinal gas, fever, tooth decay, as an aphrodisiac, and to reduce anxiety, but there is no good scientific evidence to support these uses.

6. Body Systems and Health Areas Associated with Vanilla and Vanillin

• Nervous System: Vanillin is largely used as flavoring and in the cosmetic industry. Besides its industrial use, this natural compound possesses several beneficial effects for human health, mainly due to its strong antioxidant activity, in addition to its anti-inflammatory, anti-mutagenic, anti-metastatic, and anti-depressant properties.
• Hematological System: Vanillin has been the foundational research molecule for anti-sickling therapy in sickle cell disease, acting by covalently binding hemoglobin S and stabilizing the high-oxygen-affinity state.
• Hepatic System: Preclinical animal models show hepatoprotective effects mediated through suppression of oxidative stress and inflammatory cytokines.
• Gastrointestinal System: Findings suggest that vanillin can play a key role in clinical applications via the regulation of gut microbial dysbiosis.
• Oncological: Preclinical in vitro and animal evidence exists for antimutagenic and anti-metastatic activity across multiple cancer cell types, though with conflicting findings at high doses.
• Reproductive System: Mouse model data suggests potential in endometriosis through anti-inflammatory and anti-proliferative pathways.
• Skin and Integument: The sap of most species of Vanilla orchid can cause moderate to severe dermatitis if it comes in contact with bare skin, though it is water-soluble and can be removed by washing. The sap of vanilla orchids contains calcium oxalate crystals, which appear to be the main causative agent of contact dermatitis in vanilla plantation workers.

7. Dosage Forms and Doses Reported in Studies

No established therapeutic dosing regimen for vanilla or vanillin as a dietary supplement has been confirmed by regulatory bodies or clinical trials. The following doses appear in the primary research literature:

• Anti-sickling (MX-1520 prodrug, mouse model): Oral doses of 137.5 and 275 mg/kg in transgenic sickle mice significantly prolonged survival time under severe hypoxic conditions (28.8 ± 12 min and 31 ± 7.5 min, respectively, vs. 6.6 ± 0.8 min in untreated animals).
• Anticarcinogenic investigation (rat model, intraperitoneal): AOM-challenged rats were treated with vanillin orally and intraperitoneally at low and high concentrations, with aberrant crypt foci density, multiplicity, and distribution observed. At 300 mg/kg body weight via intraperitoneal route, vanillin showed potentially adverse effects on aberrant crypt foci development.
• In vitro antiproliferative (colorectal cancer): Vanillin at 1000 µg/mL inhibited the proliferation of HT-29 colorectal cancer cells.
• Vanillin semicarbazone (in vivo anticancer, mouse, intraperitoneal): VSC was administered at three doses (5, 7.5, and 10 mg/kg i.p.) into the intraperitoneal cavity of EAC-inoculated mice. Among the doses studied, 10 mg/kg (i.p.) was found to be quite comparable in potency to that of the reference drug bleomycin at 0.3 mg/kg (i.p.).
• Food-grade intake: Vanillin contributes 1–2% weight/weight of the cured pods, with typical food-use exposure being at trace levels far below any studied therapeutic dose.

8. Safety Considerations and Interactions

8.1 General Safety Status

According to the US FDA, Vanilla planifolia seed, Vanilla planifolia seed powder, and Vanilla tahitensis seed are Generally Recognized As Safe (GRAS) as direct food additives and for use as spices and other natural seasonings and flavorings. Vanilla is likely safe when taken by mouth in amounts commonly found in foods.

8.2 Contact Dermatitis

Contact dermatitis due to vanillin can occur in individuals exposed in the cultivation, trade, or industrial use of vanilla. In a 24-hour, occlusive patch test involving 25 male subjects, a vanilla extract did not induce skin irritation. The same material did not induce contact sensitization in a maximization test. Some individuals are sensitized to synthetic vanillin and not to the natural spice, and vice versa.

8.3 Occupational Hazards

Vanilla may cause headache and sleep problems (insomnia), especially for people who manufacture vanilla extract. Inhalation of vanillin dust or aerosols in industrial settings may cause respiratory irritation, though this is rare in typical consumer exposure scenarios.

8.4 Bioavailability Limitations

Vanillin has no therapeutic effect if given orally for anti-sickling purposes because orally administered vanillin is rapidly decomposed in the upper digestive tract. This is a pharmacokinetic limitation relevant to all proposed systemic therapeutic applications of orally consumed vanillin. Vanillin undergoes extensive metabolism, resulting in low bioavailability, low potency, and an overall reduction in its pharmacologic effect.

8.5 Coumarin in Some Vanilla Products

Some vanilla extracts contain a chemical called coumarin, which is banned by the FDA. This is particularly a concern with extracts derived from Vanilla pompona or adulterated products. Consumers should verify that any extract is derived from genuine Vanilla planifolia beans.

8.6 High-Dose Concerns

In high concentrations, vanillin is toxic to living cells. High concentrations (300 mg/kg body weight) of vanillin administered through intraperitoneal injection in rodents could increase aberrant crypt foci density and multiplicity, highlighting that extremely high doses may exert opposing biological effects compared with lower concentrations. These doses are far beyond any amounts achievable through normal dietary consumption.

8.7 Pregnancy and Lactation

Vanilla is likely safe for pregnant and breastfeeding women when taken by mouth in food amounts. There is insufficient reliable information to know whether vanilla is safe to use as a medicine during pregnancy or breastfeeding.

8.8 Calcium Oxalate Crystals in Plant Sap

The sap of most species of Vanilla orchid, which exudes from cut stems or where pods are harvested, can cause moderate to severe dermatitis if it comes into contact with bare skin, though it is water-soluble and can be removed by washing. The sap of vanilla orchids contains calcium oxalate crystals, which appear to be the main causative agent of contact dermatitis in vanilla plantation workers.

References

• Wikipedia — Vanilla planifolia
• ScienceDirect Topics — Vanilla planifolia: Overview
• Gallage et al. (2014). Vanillin formation from ferulic acid in Vanilla planifolia is catalysed by a single enzyme. Nature Communications.
• PMC — Authentic Aroma and Compound-Specific Isotope Ratios of Vanilla Pods (V. planifolia and V. tahitensis). (2025)
• PMC — Vanilla beyond Vanilla planifolia and Vanilla × tahitensis: Taxonomy, Reproductive Biology, and Metabolites. (2022)
• New York Botanical Garden — Vanilla in Mexico
• Mexicolore — Aztec Advances in Health: Vanilla
• PMC — Vanillin: a review on the therapeutic prospects of a popular flavouring molecule. Advances in Traditional Medicine. (2021)
• PubMed — Evaluation of the antioxidant, anti-inflammatory and hepatoprotective properties of vanillin in carbon tetrachloride-treated rats. (2011)
• PubMed — Evaluation of antioxidant activity of vanillin by using multiple antioxidant assays. (2011)
• PubMed — Anti-Neuroinflammatory Effects of Vanillin Through the Regulation of Inflammatory Factors and NF-κB Signaling in LPS-Stimulated Microglia. (2018)
• PMC — Vanillin Has Potent Antibacterial, Antioxidant, and Anti-Inflammatory Activities In Vitro and in Mouse Colitis Induced by Multidrug-Resistant Escherichia coli. (2024)
• MDPI — Vanillin and Its Derivatives: A Critical Review of Their Anti-Inflammatory, Anti-Infective, Wound-Healing, Neuroprotective, and Anti-Cancer Health-Promoting Benefits. (2024)
• PMC — Antibacterial effects of vanilla ingredients provide novel treatment options for infections with multidrug-resistant bacteria. (2022)
• PMC — Overview of the Role of Vanillin in Neurodegenerative Diseases and Neuropathophysiological Conditions. Int. J. Mol. Sci. (2023)
• PubMed — Abraham et al. Vanillin, a potential agent for the treatment of sickle cell anemia. (1991)
• Wiley — Anti-sickling effect of MX-1520, a prodrug of vanillin: an in vivo study using rodents. British Journal of Haematology. (2004)
• HHS TAGGS — Aromatic Aldehyde Derivatives and Sickle Cell Disease (Award Detail)
• PMC — Rational Design of Pyridyl Derivatives of Vanillin for the Treatment of Sickle Cell Disease. (2018)
• PubMed — Vanillin prevents the growth of endometriotic lesions through anti-inflammatory and antioxidant pathways in a mouse model. (2023)
• PMC — Vanillin Differentially Affects Azoxymethane-Injected Rat Colon Carcinogenesis and Gene Expression. (2012)
• PubMed — Vanillin suppresses in vitro invasion and in vivo metastasis of mouse breast cancer cells. (2005)
• PMC — Vanillin downregulates NNMT and attenuates resistance to 5-fluorouracil via ROS-induced cell apoptosis in colorectal cancer cells. (2021)
• PMC — In vivo anticancer activity of vanillin semicarbazone. (2013)
• PMC — Antimutagenicity of Cinnamaldehyde and Vanillin in Human Cells: Global Gene Expression and Possible Role of DNA Damage and Repair. (2007)
• Cosmetic Ingredient Review — Safety Assessment of Vanilla-Derived Ingredients as Used in Cosmetics. (2018)
• WebMD Natural Medicines — Vanilla: Overview, Uses, Side Effects, Precautions
• Frontiers in Neuroscience — Ameliorative effect of vanillin on scopolamine-induced dementia-like cognitive impairment in a mouse model. (2022)
• Frontiers in Pharmacology — Binding of vanillin with human transferrin: targeting neuroinflammation in Alzheimer's disease therapeutics. (2024)